Skip to Content

ImmunoCellular Therapeutics to Present Today Data From Phase I Clinical Trial of ICT-107 at Annual Meeting of Congress of Neurological Surgeons

Company to Host Conference Call to Discuss Results on Tuesday, October 27th at 11a.m. eastern time


LOS ANGELES--(BUSINESS WIRE)--Oct 26, 2009 - ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.


The company will hold a conference call on Tuesday, October 27th at 11 a.m. eastern time to discuss the data presented at the conference. Interested parties may access the call by dialing (877) 407-0778 domestically, or (201) 689-8565 internationally. A replay of the call will be available until November 10, 2009, and can be accessed by dialing (877) 660-6853 domestically, or (201)-612-7415 for international audiences, and using account # 286 and Conference ID #: 336119.


The call will also be available via a simultaneous live webcast, and can be accessed by visiting and using InComm IQueue Conference Number: 00336119. Please note that webcast audiences must use Internet Explorer to access the broadcast.


About ImmunoCellular Therapeutics, Ltd.


IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company's “off the shelf” therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the first quarter of 2010. IMUC also recently completed a Phase I trial of its dendritic cell-based clinical product candidate for glioblastoma. IMUC has entered into a research and license option deal with the Roche Group for one of its monoclonal antibodies for the diagnosis and treatment of ovarian cancer and multiple myeloma, that provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit


About the CNS


The Congress of Neurological Surgeons, a leader in education and innovation, is dedicated to advancing neurosurgery by providing members with the educational and career development opportunities they need to become leaders and innovators in the field. The Congress of Neurological Surgeons exists to enhance health and improve lives worldwide through the advancement of education and scientific exchange.


The Congress of Neurological Surgeons serves to promote health by advancing neurosurgery worldwide through innovation and excellence in education. The Congress of Neurological Surgeons provides global leadership in neurosurgery by inspiring and facilitating scientific discovery and its translation into clinical practice. The Congress of Neurological Surgeons maintains the vitality of the profession through volunteer efforts of its members and the development of leadership in service to the public, to colleagues in other disciplines, and to neurosurgeons throughout the world in all stages of their professional lives.


Forward-Looking Statements


This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation, the risks associated with the potential inability to obtain licenses from third parties that will be needed to commercialize ICT-107 in many major commercial territories; the potential inability to secure a partner for ICT-107; the risk that future trials of ICT-107, if any, do not confirm the safety and efficacy data generated in the Phase I trial; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining a patent that provides commercially significant protection for ICT-107; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages and to continue IMUC's operations. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.










Contact: CEOcast, Inc. for ImmunoCellular Therapeutics

Gary Nash, 212-732-4300



Posted: October 2009